Several other analysts have also recently weighed in on BCPC. HC Wainwright restated a buy rating and set a $95.00 price target (down from $110.00) on shares of Balchem in a report on Monday, August 5th. Zacks Investment Research cut Balchem from a hold rating to a sell rating in a report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Balchem presently has a consensus rating of Hold and an average price target of $108.75.
Balchem stock opened at $105.34 on Thursday. Balchem has a 12-month low of $73.16 and a 12-month high of $117.79. The company has a quick ratio of 2.63, a current ratio of 3.73 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is $91.75 and its two-hundred day moving average price is $95.00. The stock has a market cap of $3.38 billion, a PE ratio of 35.00 and a beta of 1.17.
In other news, VP Scott C. Mason purchased 3,000 shares of Balchem stock in a transaction dated Monday, August 5th. The shares were bought at an average cost of $84.74 per share, for a total transaction of $254,220.00. Following the completion of the acquisition, the vice president now owns 12,524 shares in the company, valued at approximately $1,061,283.76. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP David F. Ludwig sold 12,750 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $90.00, for a total value of $1,147,500.00. Following the sale, the vice president now owns 21,038 shares in the company, valued at $1,893,420. The disclosure for this sale can be found here. Insiders own 1.28% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Moody Aldrich Partners LLC boosted its holdings in Balchem by 2.7% in the second quarter. Moody Aldrich Partners LLC now owns 62,559 shares of the basic materials company’s stock valued at $6,254,000 after acquiring an additional 1,667 shares during the last quarter. Biondo Investment Advisors LLC bought a new stake in Balchem in the second quarter valued at approximately $200,000. Wasatch Advisors Inc. boosted its holdings in Balchem by 6.3% in the first quarter. Wasatch Advisors Inc. now owns 1,232,837 shares of the basic materials company’s stock valued at $114,407,000 after acquiring an additional 73,439 shares during the last quarter. Bessemer Group Inc. boosted its holdings in Balchem by 0.5% in the second quarter. Bessemer Group Inc. now owns 50,558 shares of the basic materials company’s stock valued at $5,054,000 after acquiring an additional 258 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its holdings in Balchem by 7.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 11,853 shares of the basic materials company’s stock valued at $1,186,000 after acquiring an additional 860 shares during the last quarter. Institutional investors own 86.43% of the company’s stock.
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
See Also: What is a Tariff?
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.